MAR 1 3 2002 M

Our Reference No. 9579-14

#15/ E DM 04/12/02

111	4 IIIE OMITED	SIAIES FAIEN	I WIND I KN	IDEIMAKK OI	

in re Application of)		
Gary Levy and David A. Clark) Group Art Unit: 1644		
Serial No.: 09/442,143	 Date of Allowance: Dec. 13, 2001 Examiner: Patrick J. Nolan 		
Filed: November 15, 1999) Examiner: Fathck J. Nolan		
	BOX ISSUE FEE		
For: Methods of Modulating Immune)		
Congulation	1		

The Commissioner of Patents & Trademarks Washington, D.C. 20231 U.S.A.

Dear Sir:

El

Amendment After Allowance 37 CFR 1. 312

This is in response to the Notice of Allowability dated December 13, 2001.

in the Disclosure:

Please replace the paragraph beginning at page 5, line 7, with the following rewritten paragraphs:

--Figure 8A shows the nucleotide sequence of the mouse (SEQ.ID.NO.: 10) and human (SEQ.ID.NO.: 11) Fgl2 gene promoter regions;

Figure 8B shows the nucleotide sequence of the mouse (SEQ.ID.NO.: 10) and human (SEQ.ID.NO.: 11) Fgl2 gene promoter regions;—

Please replace the paragraph beginning at page 5, line 9, with the following rewritten paragraphs:

--Figure 9A shows the nucleic acid sequence of the transcription binding sites in the putative promoter region of hfgl2 (SEQ.ID.NO.: 12);

Figure 9B shows the nucleic acid sequence of the transcription blndlng sites in the putative promoter region of hfgl2 (SEQ.ID.NO.: 12);--